Why the study?
Does OPC-8212 improve symptoms and cardiac function in patients with dilated cardiomyopathy?
Population
8 patients with dilated cardiomyopathy (New York Heart Association functional class II-III)
Design
Case_series
Follow-up
4 to 8 weeks
Authors
Loading...
Potential benefit in small dilated cardiomyopathy cohort; leaves open clinical role pending controlled trials.
Does OPC-8212 improve symptoms and cardiac function in patients with dilated cardiomyopathy?
OPC-8212, an oral inotropic agent, demonstrated sustained enhancement of the inotropic state and symptomatic improvement over 4 to 8 weeks in a small cohort of patients with dilated cardiomyopathy.
Asanoi et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: